Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 1/20 | 0.34 |
| ▸ | CXCR4 | P61073 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.32 |
| ▸ | SPTLC1 | O15269 | 1/20 | 0.32 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4077956 | 0.89 | TBXAS1 (0.32) | TBXAS1CXCR4DGAT1 | |
| SCHEMBL4067316 | 0.88 | DUT (0.37) | TBXAS1CXCR4DGAT1 | |
| SCHEMBL1794846 | 0.77 | DGAT1 (0.37) | DGAT1NR1H3 | |
| SCHEMBL2647731 | 0.70 | DGAT1 (0.36) | DGAT1KLKB1 | |
| SCHEMBL2970649 | 0.69 | NPC1 (0.36) | TBXAS1DGAT1KLKB1 | |
| SCHEMBL4067312 | 0.69 | DUT (0.33) | — | |
| SCHEMBL4772025 | 0.69 | LMNA (0.32) | DGAT1AGTR1AGTR2KLKB1 | |
| SCHEMBL4206991 | 0.68 | KLKB1 (0.33) | DGAT1KLKB1 | |
| SCHEMBL4196846 | 0.68 | KLKB1 (0.35) | TBXAS1DGAT1AGTR1AGTR2KLKB1 | |
| SCHEMBL2984964 | 0.67 | DGAT1 (0.36) | DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2055705-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | Ono Pharmaceutical CO., LTD. (JP) | 2009-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325992-A1 | COMPOUND HAVING CYCLIC GROUP BOUND THERETO THROUGH SPIRO BINDING AND USE THEREOF | CXCR4, CXCL12, CXCR1 | TBXAS1 1114/4885CXCR4 1/4885DGAT1 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.